BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells
Ronald Schilderink(Foundation for Liver and Gastrointestinal Research), Wouter J. de Jonge(University of Bonn), Eleonora Reginato(GlaxoSmithKline (United Kingdom)), Pawel A. Kabala(Amsterdam UMC Location University of Amsterdam), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), David F. Tough(Jenner Institute), Inmaculada Rioja(Bicycle Therapeutics (United Kingdom)), Kris A. Reedquist(Utrecht University), Chris Patten(GlaxoSmithKline (United Kingdom)), Matthew Bell(GlaxoSmithKline (United Kingdom)), Paul P. Tak(Celldex Therapeutics (United States)), Francisca W. Hilbers
Cited by 35
Related Papers
NF-κB: a key role in inflammatory diseases
|Journal of Clinical Investigation|2001|3.9k
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway
|Nature Immunology|2005|1.1k